Cardiac AI startup UltraSight secures US$24 million for US expansion

UltraSight has raised US$24m to expand its AI-guided cardiac ultrasound platform across US hospitals and develop intensive care and circulatory support workflows.

The Israeli company said the Series B2 financing will support wider adoption of its Echosystem platform in the US and the development of additional tools for clinical settings where rapid imaging can directly affect treatment decisions.

The platform combines structured training, real-time AI guidance and advanced analytics to help trained clinical providers perform focused echocardiography examinations under qualified physician oversight.

UltraSight said its Echosystem is currently deployed at more than 10 commercial sites, including intensive care settings.

Davidi Vortman, chief executive and co-founder of UltraSight, said: “We are entering this next stage as our FDA-cleared portfolio continues to expand to support broader cardiac imaging workflows.

“This financing will help our efforts to translate that momentum into wider market adoption, deeper strategic collaborations and greater access to high-quality cardiac ultrasound – expediting care for patients who simply cannot afford to wait.”

The financing was led by Alive HealthTech Growth Fund, with participation from Deep Insight, Star51 Capital, Connecticut Innovations and eHealth Ventures.

Existing investors Mayo Clinic Ventures, NYU and Iron Nation also participated.

Dudi Klein, Alive co-founder and managing partner, said: “UltraSight combines clinical evidence with a scalable commercial model in a market constrained by access and workforce shortages.

“We believe the company has developed technology, leadership, and strategic collaborations that position it to support the evolution of cardiac workflows across care settings.”

A recent study found that novice operators using the company’s AI guidance were able to acquire cardiac ultrasound images.

The images were used for automated detection of moderate or greater aortic stenosis.

The study reported 93 per cent sensitivity and 96 per cent specificity.

UltraSight said the findings support the potential use of AI-guided ultrasound to broaden access to cardiac screening in different care settings and identify patients who may need further evaluation.